Presentation is loading. Please wait.

Presentation is loading. Please wait.

Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen- specific immunotherapy  Roberto González-Rioja, PhD, Ignacio Ibarrola,

Similar presentations


Presentation on theme: "Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen- specific immunotherapy  Roberto González-Rioja, PhD, Ignacio Ibarrola,"— Presentation transcript:

1 Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen- specific immunotherapy  Roberto González-Rioja, PhD, Ignacio Ibarrola, PhD, M. Carmen Arilla, PhD, Angel Ferrer, MD, PhD, Amparo Mir, MD, PhD, Carmen Andreu, MD, Alberto Martínez, PhD, Juan A. Asturias, PhD  Journal of Allergy and Clinical Immunology  Volume 120, Issue 3, Pages (September 2007) DOI: /j.jaci Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Schematic construction of hybrid proteins. Identified T-cell epitope regions and putative IgE-binding epitope regions are marked by yellow and green, respectively. Numbering indicates amino acid position, and primers are indicated by arrows. Disulfide bridges are indicated by straight lines at the top of the scheme. Dashed lines show deleted stretches. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 A, Coomassie-stained SDS-PAGE and IgE Western blotting of NPA (lane 1), Q1 (lane 2), Q2 (lane 3), and Q3 (lane 4) incubated with the serum pool of patients with P judaica allergy. The arrowhead indicates the IgE-reacting band of Q2. B, CD spectra of NPA and the hybrid molecules. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 A, Box plot representation of duplicate specific IgE means from individual patient sera (n = 30) to P judaica pollen extract, NPA, Q1, Q2, and Q3. Outliers are indicated by open circles. B, ELISA inhibition curves. The binding of human IgE from the serum pool to P judaica pollen extract was inhibited by using NPA and Q1, Q2, and Q3 hybrid proteins. Values represent the mean + SD (n = 3). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 A, SPT results from individual patients (n = 30) with P judaica pollen extract: NPA and Q1 (both at 50 μg/mL) and Q2 and Q3 (both at 250 μg/mL) are shown. B, Induction of T-cell proliferation. PBMCs from individual patients (n = 13) were stimulated with 500 ng/mL P judaica pollen extract, NPA, Q1, Q2, and Q3. Individual values are given as means of duplicate wheal surface areas and of triplicate stimulation index (SI) percentages, respectively. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2007 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen- specific immunotherapy  Roberto González-Rioja, PhD, Ignacio Ibarrola,"

Similar presentations


Ads by Google